Predicting benefit of endocrine therapy for early breast cancer

被引：2

作者：

Regan, Meredith M. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

BREAST | 2015年 / 24卷

关键词：

Adjuvant therapy; Aromatase inhibitor; Postmenopausal; Premenopausal; Tamoxifen; INTERNATIONAL EXPERT CONSENSUS; 1-98; RANDOMIZED-TRIAL; OVARIAN SUPPRESSION; WOMEN; HIGHLIGHTS; TAMOXIFEN; RISK;

D O I：

10.1016/j.breast.2015.07.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant endocrine therapy is a mainstay of treatment for patients with endocrine-responsive early breast cancer. Questions remain concerning which patients should receive what type of endocrine therapy and for how long. Several factors have been considered as potential indicators to predict benefit of endocrine therapy, including patient factors, clinico-pathological factors and multigene assays. To date, factors associated with risk of recurrence have been the most widely adopted to influence treatment selection. The International Breast Cancer Study Group (IBCSG)-led adjuvant endocrine therapy trials BIG 1-98, for postmenopausal women, and SOFT and TEXT, for premenopausal women, can shed light on the role for risk of recurrence in identifying who should receive which type of adjuvant endocrine therapy and for how long. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：S129 / S131

页数：3

共 10 条

[1] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Coates, Alan S.
Keshaviah, Aparna
Thuerlimann, Beat
Mouridsen, Henning
Mauriac, Louis
Forbes, John F.
Paridaens, Robert
Castiglione-Gertsch, Monica
Gelber, Richard D.
Colleoni, Marco
Lang, Istvan
Del Mastro, Lucia
Smith, Ian
Chirgwin, Jacquie
Nogaret, Jean-Marie
Pienkowski, Tadeusz
Wardley, Andrew
Jakobsen, Erik H.
Price, Karen N.
Goldhirsch, Aron
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 486 - 492
[2] Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, Prudence A.
Regan, Meredith M.
Fleming, Gini F.
Lang, Istvan
Ciruelos, Eva
Bellet, Meritxell
Bonnefoi, Herve R.
Climent, Miguel A.
Da Prada, Gian Antonio
Burstein, Harold J.
Martino, Silvana
Davidson, Nancy E.
Geyer, Charles E., Jr.
Walley, Barbara A.
Coleman, Robert
Kerbrat, Pierre
Buchholz, Stefan
Ingle, James N.
Winer, Eric P.
Rabaglio-Poretti, Manuela
Maibach, Rudolf
Ruepp, Barbara
Giobbie-Hurder, Anita
Price, Karen N.
Colleoni, Marco
Viale, Giuseppe
Coates, Alan S.
Goldhirsch, Aron
Gelber, Richard D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05) : 436 - 446
[3] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch, A.
Winer, E. P.
Coates, A. S.
Gelber, R. D.
Piccart-Gebhart, M.
Thuerlimann, B.
Senn, H. -J.
[J]. ANNALS OF ONCOLOGY, 2013, 24 (09) : 2206 - 2223
[4] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
Goldhirsch, A.
Ingle, J. N.
Gelber, R. D.
Coates, A. S.
Thuerlimann, B.
Senn, H. -J.
[J]. ANNALS OF ONCOLOGY, 2009, 20 (08) : 1319 - 1329
[5] Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
Lazar, Ann A.
Cole, Bernard F.
Bonetti, Marco
Gelber, Richard D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4539 - 4544
[6] Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, Olivia
Regan, Meredith M.
Walley, Barbara A.
Fleming, Gini F.
Colleoni, Marco
Lang, Istvan
Gomez, Henry L.
Tondini, Carlo
Burstein, Harold J.
Perez, Edith A.
Ciruelos, Eva
Stearns, Vered
Bonnefoi, Herve R.
Martino, Silvana
Geyer, Charles E., Jr.
Pinotti, Graziella
Puglisi, Fabio
Crivellari, Diana
Ruhstaller, Thomas
Winer, Eric P.
Rabaglio-Poretti, Manuela
Maibach, Rudolf
Ruepp, Barbara
Giobbie-Hurder, Anita
Price, Karen N.
Bernhard, Juerg
Luo, Weixiu
Ribi, Karin
Viale, Giuseppe
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Francis, Prudence A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) : 107 - 118
[7] Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer:: supplementary results from the BIG 1-98 randomised trial
Rasmussen, Birgitte B.
Regan, Meredith M.
Lykkesfeldt, Anne E.
Dell'Orto, Patrizia
Del Curto, Barbara
Henriksen, Katrine L.
Mastropasqua, Mauro G.
Price, Karen N.
Mery, Eliane
Lacroix-Triki, Magali
Braye, Stephen
Altermatt, Hans J.
Gelber, Richard D.
Castiglione-Gertsch, Monica
Goldhirsch, Aron
Gusterson, Barry A.
Thurlimann, Beat
Coates, Alan S.
Viale, Giuseppe
[J]. LANCET ONCOLOGY, 2008, 9 (01) : 23 - 28
[8] Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials
Regan, Meredith M.
Pagani, Olivia
Fleming, Gini F.
Walley, Barbara A.
Price, Karen N.
Rabaglio, Manuela
Maibach, Rudolf
Ruepp, Barbara
Coates, Alan S.
Goldhirsch, Aron
Colleoni, Marco
Gelber, Richard D.
Francis, Prudence A.
[J]. BREAST, 2013, 22 (06) : 1094 - 1100
[9] Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
Sestak, Ivana
Cuzick, Jack
Dowsett, Mitch
Lopez-Knowles, Elena
Filipits, Martin
Dubsky, Peter
Cowens, John Wayne
Ferree, Sean
Schaper, Carl
Fesl, Christian
Gnant, Michael
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 916 - +
[10] Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale, G.
Regan, M. M.
Dell'Orto, P.
Mastropasqua, M. G.
Maiorano, E.
Rasmussen, B. B.
MacGrogan, G.
Forbes, J. F.
Paridaens, R. J.
Colleoni, M.
Lang, I.
Thuerlimann, B.
Mouridsen, H.
Mauriac, L.
Gelber, R. D.
Price, K. N.
Goldhirsch, A.
Gusterson, B. A.
Coates, A. S.
[J]. ANNALS OF ONCOLOGY, 2011, 22 (10) : 2201 - 2207

← 1 →